European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Baricitinib (Primary) ; Baricitinib (Primary) ; Bemcentinib (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms Bari-SolidAct; EU-SolidAct; SolidAct
- 02 Feb 2023 Status changed from recruiting to discontinued.
- 27 Sep 2022 According to BerGenBio media release, the first patient has been included in a study of BerGenBios oral, highly selective AXL inhibitor, bemcentinib, as part of this EU-SolidAct trial in hospitalized COVID-19 patients
- 26 Jan 2022 According to BerGenBio media release, EU-SolidAct has established clinical sites in 15 countries. The trial is sponsored by Oslo University Hospital, Norway in collaboration with the Institut National de la Sante Et de la Recherche Medicale (Inserm), France and the not-for-profit intergovernmental organization European Clinical Research Infrastructure Network (ECRIN). The EU-SolidAct trial is part of EU-RESPONSE.